This site is archived and is no longer updated. It will be taken offline in mid-July. All the latest AWMSG recommendations, guidance and information is available on our new website at:
awmsg logo

elosulfase alfa (Vimizim®)

Reference No. 1084

Publication date:

Appraisal information

elosulfase alfa (Vimizim®) 1 mg/ml concentrate for solution for infusion

Company: BioMarin Europe Ltd
BNF category: Nutrition and blood
NMG meeting date: Not scheduled
AWMSG meeting date: 24/02/2016
Submission Type: NICE HST
Status: Recommended
Advice No: Not available
Ratification by Welsh Government: 16/03/2016

Current Progress

Ratification by
Welsh Government

AWMSG advice

The National Institute for Health and Care Excellence (NICE) published advice in December 2015 in relation to elosulfase alfa (Vimizim®) for the treatment of patients with mucopolysaccharidosis, type IVA (Morquio A Syndrome, MPS IVA). At their meeting on 24 February 2016 AWMSG supported the adoption and implementation of this advice within NHS Wales (refer to the minutes of meetings). The Minister for Health and Social Services has subsequently agreed that the NICE HST advice for elosulfase alfa (Vimizim®) should be implemented within NHS Wales. Refer to the NICE website for full guidance including any specific restrictions on the use of the technology.